In vitro and in vivo evaluation of the main protease inhibitor FB2001 against SARS-CoV-2

Weijuan Shang, Wenhao Dai, Cheng Yao, Ling Xu, Xiangming Tao, Haixia Su, Jian Li, Xiong Xie, Yechun Xu, Min Hu, Dong Xie, Hualiang Jiang, Leike Zhang, Hong Liu, Weijuan Shang, Wenhao Dai, Cheng Yao, Ling Xu, Xiangming Tao, Haixia Su, Jian Li, Xiong Xie, Yechun Xu, Min Hu, Dong Xie, Hualiang Jiang, Leike Zhang, Hong Liu

Abstract

FB2001 is a drug candidate that targets the main protease of SARS-CoV-2 via covalently binding to cysteine 145. In this study, we evaluated the inhibitory activities of FB2001 against several SARS-CoV-2 variants in vitro and in vivo (in mice), and we also evaluated the histopathological analysis and immunostaining of FB2001 on lung and brain which have been rarely reported. The results showed that FB2001 exhibited potent antiviral efficacy against several current SARS-CoV-2 variants in Vero E6 cells, namely, B.1.1.7 (Alpha): EC50 = 0.39 ± 0.01 μM, EC90 = 0.75 ± 0.01 μM; B.1.351 (Beta): EC50 = 0.28 ± 0.11 μM, EC90 = 0.57 ± 0.21 μM; B.1.617.2 (Delta): EC50 = 0.27 ± 0.05 μM, EC90 = 0.81 ± 0.20 μM; B.1.1.529 (Omicron): EC50 = 0.26 ± 0.06 μM and EC50 = 0.042 ± 0.007 μM (in the presence of a P-glycoprotein inhibitor). FB2001 remained potent against SARS-CoV-2 replication in the presence of high concentrations of human serum, which indicating that human serum had no significant effect on the in vitro inhibitory activity. Additionally, this inhibitor exhibited an additive effect against SARS-CoV-2 when combined with Remdesivir. Furthermore, FB2001 significantly reduced the SARS-CoV-2 copy numbers and titers in the lungs and brains in vivo, and alleviated the pathological symptoms. In addition, FB2001 could alleviated local bleeding, erythrocyte overflow, edema, and inflammatory cell infiltration in brain tissue, and inhibitors reducing viral titers and improving inflammation in the brain have been rarely reported. A physiologically based pharmacokinetic model was established and verified to predict the FB2001 concentration in human lungs. When FB2001 was administered at 200 mg twice a day for 5 days, the observed Ctrough ss in plasma and predicted Ctrough ss of lung total concentration were 0.163 and 2.5 μg/mL, which were approximately 9 and 132-fold higher than the EC50 of 0.019 μg/mL (0.042 μM) against Omicron variant. Taken together, our study suggests that FB2001 is a promising therapeutic agent in COVID-19 treatment and can be combined with remdesivir to achieve improved clinical outcomes. Owing to its good safety and tolerability in healthy human (NCT05197179 and NCT04766931), FB2001 has been approved for Phase II/III clinical trial (NCT05445934).

Keywords: Anti-SARS-CoV-2 in vivo; FB2001; Main protease; PBPK; SARS-CoV-2; SARS-CoV-2 variants.

Conflict of interest statement

Declaration of competing interest The author(s) declared no potential conflicts of interest with respect to the research.

Copyright © 2022 Elsevier B.V. All rights reserved.

Figures

Graphical abstract
Graphical abstract
Fig. 1
Fig. 1
Comparing the Mproof SARS-CoV-2 with four SARS-CoV-2 variants of concern (VOCs). (A) FB2001 is a reversible inhibitor of SARS-CoV-2 Mpro as demonstrated by recovery of enzymatic activity. (B) Sequence alignment of Mpro in SARS-CoV-2 and several variants, wild-type, B.1.1.7 (Alpha), B.1.351 (Beta), B.1.617.2 (Delta), and B.1.1.529 (Omicron). (C) An X-ray crystal structure of SARS-CoV-2 Mpro in complex with FB2001 (PDB code: 6LZE). Compound FB2001 is shown as pink sticks. K90, P132 and FB2001 are indicated by red spheres, pink spheres and pink sticks, respectively.
Fig. 2
Fig. 2
Synergistic analysis of FB2001 combined with remdesivir. Where −10 < synergy score <10 indicates an additive effect, synergy score < −10 indicates an antagonistic effect, and synergy score >10 indicates a synergistic effect.
Fig. 3
Fig. 3
In vivo efficacy of FB2001 in K18-hACE2 mice infected with SARS-CoV-2 delta variant. The transgenic K18-hACE2 mice were divided into 3 groups: Vehicle control group, FB2001-100 mg/kg (100 mpk) group and FB2001-200 mg/kg (200 mpk) group. 7 mice per group. Transgenic mice in treatment group were challenged with SARS-CoV-2 delta variant by nasal drip. (A) Experiment flow diagram. (B, C) Viral titer in lung on Day 2 and 4 after SARS-CoV-2 challenge (Log10 PFU/g). Dotted line represents the limit of detection of virus titration. (D) Viral titer in brain on Day 4 after SARS-CoV-2 challenge (Log10 PFU/g). Dotted line represents the limit of detection of virus titration.
Fig. 4
Fig. 4
FB2001 protects lung and brain tissue from damage caused by SARS-CoV-2 delta variant. (A-L) Representative H&E images of lung histopathology from vehicle-and FB2001-treated K18-hACE2 mice at 2 dpi and 4 dpi. Vehicle group (A-B: day 2 and G-H: day 4); FB2001 group treated with 100 mpk drug (C-D: day 2 and I-J: day 4); FB2001 group treated with 200 mpk drug (E-F: day 2 and K-L: day 4). (M-R) Representative H&E images of brain histopathology from vehicle-and FB2001-treated K18-hACE2 mice at day 4. Vehicle group (M-N); FB2001 group treated with 100 mpk drug (O-P); FB2001 group treated with 200 mpk drug (Q-R). Scale bar: A, C, E, G, I, K, M, O, Q = 1000 μm; B, D, F, H, J, L, N, P, R = 50 μm.

References

    1. Anirudhan V., Lee H., Cheng H., Cooper L., Rong L. Targeting SARS-CoV-2 viral proteases as a therapeutic strategy to treat COVID-19. J. Med. Virol. 2021;93:2722–2734. doi: 10.1002/jmv.26814.
    1. Boras B., Jones R.M., Anson B.J., Arenson D., Aschenbrenner L., Bakowski M.A., Beutler N., Binder J., Chen E., Eng H., et al. Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19. Nat. Commun. 2021;12:6055. doi: 10.1038/s41467-021-26239-2.
    1. Brown A.J., Won J.J., Graham R.L., Dinnon K.H., 3rd, Sims A.C., Feng J.Y., Cihlar T., Denison M.R., Baric R.S., Sheahan T.P. Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase. Antivir. Res. 2019;169 doi: 10.1016/j.antiviral.2019.104541.
    1. Choy K.T., Wong A.Y., Kaewpreedee P., Sia S.F., Chen D., Hui K.P.Y., Chu D.K.W., Chan M.C.W., Cheung P.P., Huang X., et al. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. Antivir. Res. 2020;178 doi: 10.1016/j.antiviral.2020.104786.
    1. Dai W., Zhang B., Jiang X.M., Su H., Li J., Zhao Y., Xie X., Jin Z., Peng J., Liu F., et al. Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. Science. 2020;368:1331–1335. doi: 10.1126/science.abb4489.
    1. de Erausquin G.A., Snyder H., Carrillo M., Hosseini A.A., Brugha T.S., Seshadri S., Consortium C.S.-C.-. The chronic neuropsychiatric sequelae of COVID-19: the need for a prospective study of viral impact on brain functioning. Alzheimers Dement. 2021;17:1056–1065. doi: 10.1002/alz.12255.
    1. de Wit E., Feldmann F., Cronin J., Jordan R., Okumura A., Thomas T., Scott D., Cihlar T., Feldmann H. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proc. Natl. Acad. Sci. U.S.A. 2020;117:6771–6776. doi: 10.1073/pnas.1922083117.
    1. Douaud G., Lee S., Alfaro-Almagro F., Arthofer C., Wang C., McCarthy P., Lange F., Andersson J.L.R., Griffanti L., Duff E., et al. SARS-CoV-2 is associated with changes in brain structure in UK Biobank. Nature. 2022;604:697–707. doi: 10.1038/s41586-022-04569-5.
    1. Gulati A., Boudinot F.D., Gerk P.M. Binding of lopinavir to human alpha1-acid glycoprotein and serum albumin. Drug Metab. Dispos. 2009;37:1572–1575. doi: 10.1124/dmd.109.026708.
    1. Hoffman R.L., Kania R.S., Brothers M.A., Davies J.F., Ferre R.A., Gajiwala K.S., He M., Hogan R.J., Kozminski K., Li L.Y., et al. Discovery of ketone-based covalent inhibitors of coronavirus 3CL proteases for the potential therapeutic treatment of COVID-19. J. Med. Chem. 2020;63:12725–12747. doi: 10.1021/acs.jmedchem.0c01063.
    1. Ianevski A., Giri A.K., Aittokallio T. SynergyFinder 2.0: visual analytics of multi-drug combination synergies. Nucleic Acids Res. 2020;48:W488–W493. doi: 10.1093/nar/gkaa216.
    1. Islam M.M., Gurung A.B., Bhattacharjee A., Aguan K., Mitra S. Human serum albumin reduces the potency of acetylcholinesterase inhibitor based drugs for Alzheimer's disease. Chem. Biol. Interact. 2016;249:1–9. doi: 10.1016/j.cbi.2016.02.012.
    1. Jayk Bernal A., Gomes da Silva M.M., Musungaie D.B., Kovalchuk E., Gonzalez A., Delos Reyes V., Martin-Quiros A., Caraco Y., Williams-Diaz A., Brown M.L., et al. Molnupiravir for oral treatment of covid-19 in nonhospitalized patients. N. Engl. J. Med. 2022;386:509–520. doi: 10.1056/NEJMoa2116044.
    1. Kalil A.C., Patterson T.F., Mehta A.K., Tomashek K.M., Wolfe C.R., Ghazaryan V., Marconi V.C., Ruiz-Palacios G.M., Hsieh L., Kline S., et al. Baricitinib plus remdesivir for hospitalized adults with covid-19. N. Engl. J. Med. 2021;384:795–807. doi: 10.1056/NEJMoa2031994.
    1. Kotaki T., Xie X., Shi P.Y., Kameoka M. A PCR amplicon-based SARS-CoV-2 replicon for antiviral evaluation. Sci. Rep. 2021;11:2229. doi: 10.1038/s41598-021-82055-0.
    1. Lamb Y.N. Remdesivir: first approval. Drugs. 2020;80:1355–1363. doi: 10.1007/s40265-020-01378-w.
    1. Mahase E. Covid-19: pfizer's paxlovid is 89% effective in patients at risk of serious illness, company reports. BMJ. 2021;375:n2713. doi: 10.1136/bmj.n2713.
    1. Marei H.E., Althani A., Afifi N., Pozzoli G., Caceci T., Angelini F., Cenciarelli C. Pandemic COVID-19 caused by SARS-CoV-2: genetic structure, vaccination, and therapeutic approaches. Mol. Biol. Rep. 2021;48:6513–6524. doi: 10.1007/s11033-021-06630-4.
    1. Owen D.R., Allerton C.M.N., Anderson A.S., Aschenbrenner L., Avery M., Berritt S., Boras B., Cardin R.D., Carlo A., Coffman K.J., et al. An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19. Science. 2021;374:1586–1593. doi: 10.1126/science.abl4784.
    1. Pizzorno A., Padey B., Dubois J., Julien T., Traversier A., Duliere V., Brun P., Lina B., Rosa-Calatrava M., Terrier O. In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2. Antivir. Res. 2020;181 doi: 10.1016/j.antiviral.2020.104878.
    1. Schloer S., Brunotte L., Mecate-Zambrano A., Zheng S., Tang J., Ludwig S., Rescher U. Drug synergy of combinatory treatment with remdesivir and the repurposed drugs fluoxetine and itraconazole effectively impairs SARS-CoV-2 infection in vitro. Br. J. Pharmacol. 2021;178:2339–2350. doi: 10.1111/bph.15418.
    1. Sheahan T.P., Sims A.C., Graham R.L., Menachery V.D., Gralinski L.E., Case J.B., Leist S.R., Pyrc K., Feng J.Y., Trantcheva I., et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci. Transl. Med. 2017;9 doi: 10.1126/scitranslmed.aal3653.
    1. Simsek-Yavuz S., Komsuoglu Celikyurt F.I. An update of anti-viral treatment of COVID-19. Turk. J. Med. Sci. 2021;51:3372–3390. doi: 10.3906/sag-2106-250.
    1. Thiel V., Ivanov K.A., Putics A., Hertzig T., Schelle B., Bayer S., Weissbrich B., Snijder E.J., Rabenau H., Doerr H.W., et al. Mechanisms and enzymes involved in SARS coronavirus genome expression. J. Gen. Virol. 2003;84:2305–2315. doi: 10.1099/vir.0.19424-0.
    1. Tregoning J.S., Flight K.E., Higham S.L., Wang Z., Pierce B.F. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nat. Rev. Immunol. 2021;21:626–636. doi: 10.1038/s41577-021-00592-1.
    1. Unoh Y., Uehara S., Nakahara K., Nobori H., Yamatsu Y., Yamamoto S., Maruyama Y., Taoda Y., Kasamatsu K., Suto T., et al. Discovery of S-217622, a noncovalent oral SARS-CoV-2 3CL protease inhibitor clinical candidate for treating COVID-19. J. Med. Chem. 2022;65:6499–6512. doi: 10.1021/acs.jmedchem.2c00117.
    1. Vuong W., Khan M.B., Fischer C., Arutyunova E., Lamer T., Shields J., Saffran H.A., McKay R.T., van Belkum M.J., Joyce M.A., et al. Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication. Nat. Commun. 2020;11:4282. doi: 10.1038/s41467-020-18096-2.
    1. Wang M., Cao R., Zhang L., Yang X., Liu J., Xu M., Shi Z., Hu Z., Zhong W., Xiao G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30:269–271. doi: 10.1038/s41422-020-0282-0.
    1. Yang H., Bartlam M., Rao Z. Drug design targeting the main protease, the Achilles' heel of coronaviruses. Curr. Pharmaceut. Des. 2006;12:4573–4590. doi: 10.2174/138161206779010369.
    1. Zhang L., Lin D., Sun X., Curth U., Drosten C., Sauerhering L., Becker S., Rox K., Hilgenfeld R. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved alpha-ketoamide inhibitors. Science. 2020;368:409–412. doi: 10.1126/science.abb3405.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever